Stock Analiz

Abbott Laboratories (ABT) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Abbott Laboratories’s revenue went from $20.9B in fiscal 2016 to $44.3B in fiscal 2025, growth of about 8.7% a year.

Net income in fiscal 2025 was $6.5B, a net margin of 14.7%; the best year in this period was 2024 with $13.4B.

Over the twelve months to September 30, 2026, revenue was $48.2B and net income $4.7B.

Free cash flow was $7.4B in fiscal 2025 and positive in 10 of the 10 years shown.

The diluted share count rose 18% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $20.9B162017: $27.4B172018: $30.6B182019: $31.9B192020: $34.6B202021: $43.1B212022: $43.7B222023: $40.1B232024: $42.0B242025: $44.3B25$44.3B
Net income
2016: $1.4B162017: $477M172018: $2.4B182019: $3.7B192020: $4.5B202021: $7.1B212022: $6.9B222023: $5.7B232024: $13.4B242025: $6.5B25$6.5B
Free cash flow
2016: $2.1B162017: $4.4B172018: $4.9B182019: $4.5B192020: $5.7B202021: $8.6B212022: $7.8B222023: $5.1B232024: $6.4B242025: $7.4B25$7.4B
EPS (diluted)
2016: $0.94162017: $0.27172018: $1.33182019: $2.06192020: $2.50202021: $3.94212022: $3.91222023: $3.26232024: $7.64242025: $3.7225$3.72

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$48.2B$44.3B$42.0B$40.1B$43.7B$43.1B$34.6B$31.9B$30.6B$27.4B$20.9B
Gross profit$27.5B$25.0B$23.2B$22.1B$24.5B$24.5B$19.6B$18.7B$17.9B$15.0B$11.8B
Operating income$6.6B$8.1B$6.8B$6.5B$8.4B$8.4B$5.4B$4.5B$3.6B$1.6B$3.0B
Net income$4.7B$6.5B$13.4B$5.7B$6.9B$7.1B$4.5B$3.7B$2.4B$477M$1.4B
EPS (diluted)$2.69$3.72$7.64$3.26$3.91$3.94$2.50$2.06$1.33$0.27$0.94
R&D$3.3B$2.9B$2.8B$2.7B$2.9B$2.7B$2.4B$2.4B$2.3B$2.3B$1.4B
Revenue growth—+5.7%+4.6%−8.1%+1.3%+24.5%+8.5%+4.3%+11.6%+31.4%+2.2%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$8.9B$9.6B$8.6B$7.3B$9.6B$10.5B$7.9B$6.1B$6.3B$5.6B$3.2B
Capital spending-$2.1B-$2.2B-$2.2B-$2.2B-$1.8B-$1.9B-$2.2B-$1.6B-$1.4B-$1.1B-$1.1B
Free cash flow$6.8B$7.4B$6.4B$5.1B$7.8B$8.6B$5.7B$4.5B$4.9B$4.4B$2.1B
Dividends paid$4.3B$4.1B$3.8B$3.6B$3.3B$3.2B$2.6B$2.3B$2.0B$1.8B$1.5B
Buybacks$1.5B$893M$1.3B$1.2B$3.8B$2.3B$403M$718M$238M$117M$522M
Stock-based pay$735M$664M$673M$644M$685M$640M$546M$519M$477M$406M$310M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$8.9B$8.0B$7.3B$10.2B$10.2B$7.1B$4.1B$4.1B$9.6B$18.8B
Debt—$14.1B$15.3B$15.9B$17.9B$19.3B$19.7B$18.9B$19.4B$27.7B$20.7B
Equity—$52.1B$47.7B$38.6B$36.7B$35.8B$32.8B$31.1B$30.5B$30.9B$20.5B
Total assets—$86.7B$81.4B$73.2B$74.4B$75.2B$72.5B$67.9B$67.2B$76.2B$52.7B
Shares (diluted)1.74B1.75B1.75B1.75B1.76B1.79B1.79B1.78B1.77B1.75B1.48B

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin56.9%56.4%55.4%55.2%56.1%57.0%56.6%58.5%58.5%54.7%56.4%
Operating margin13.8%18.2%16.3%16.2%19.2%19.6%15.5%14.2%11.9%5.7%14.5%
Net margin9.7%14.7%31.9%14.3%15.9%16.4%13.0%11.6%7.7%1.7%6.7%
FCF margin14.0%16.7%15.1%12.6%17.9%20.1%16.5%14.1%16.0%16.2%10.0%
ROIC—9.4%8.6%10.2%12.8%13.2%9.2%8.2%5.9%2.1%5.5%
ROE—12.5%28.1%14.8%18.9%19.8%13.7%11.9%7.8%1.5%6.8%

Frequently asked questions

What is Abbott Laboratories’s annual revenue?

$44.3B in fiscal 2025 and $48.2B over the twelve months to September 30, 2026.

How much profit does Abbott Laboratories make?

Net income was $6.5B in fiscal 2025 (net margin 14.7%).

Is Abbott Laboratories’s revenue growing?

Yes: revenue rose 5.7% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.